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Abstract 
The public health crisis is started with emergence of new coronavirus on 11 February 2020 which triggered as 
coronavirus disease-2019 (COVID-19) pandemics. The causative agent in COVID-19 is made up of positively 
wrapped single-stranded RNA viruses ~ 30 kb in size. The epidemiology, clinical features, pathophysiology, and 
mode of transmission have been documented well in many studies, with additional clinical trials are running for 
several antiviral agents. The spreading potential of COVID-19 is faster than its two previous families, the severe 
acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-
CoV). Apart from clinical manifestation, comorbid status is playing key role for prevalence of COVID-19 infection 
and mortalities. The comorbid effects associated with COVID-19 are diabetes, cardiovascular, digestive, hepatitis-B, 
cerebrovascular, hypertension, liver injury, coronary heart disease, cancer, rheumatoid arthritis, and neurological 
impairment. Antimalarial drugs (chloroquine and hydroxychloroquine), remdesivir, Tocilizumab, 
clopinavir/ritonavir, convalescent plasma therapy, spike protein-angiotensin-converting enzyme 2 (ACE2) inhibitors, 
human monoclonal antibodies, mRNA-1273, mesenchymal stem cells, Indian and Chinese traditional medicine, 
small molecules antioxidant, natural products and dietary supplements, high doses of vitamin-E, -C, -D, minerals, 
flavonoids,and IFN-beta are therapeutic intervention running to develop treatment against COVID-19. Although 
clinical usage of these therapeutic agents against COVID-19 is well documented, cytokine storms, absence of 
appropriate animal model have limited its therapeutic use. This review explores the clinical information currently 
available on COVID-19 on the mechanisms of infection, prevention, management, comorbid status, and current 
drug treatment options. 
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Abbreviation 
WHO: World Health Organization; CNS: Central nervous system; CVD: cardiovascular disease; MAS: Macrophage 
activation system; CT-Computed tomography; SARS: Severe acute respiratory syndrome; MERS-CoV: Middle East 
respiratory syndrome coronavirus; COVID- 19:Coronavirus disease-2019; 2019-nCoV: Novel 2019 coronavirus; 
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; TMPRSS2-: Transmembrane protease serine 2; 
ACE2: Angiotensinconverting enzyme 2; RDRP-RNA-polymerase RNA-dependent; IBD: Inflammatory bowel disease 
(IBD); IFPMA: International Federation of Pharmaceutical Manufacturers; DCVMN: Developing Countries Vaccine 
Manufacturers’ Network; OP: Oropharyngeal; RCTs: Randomized controlled trials; ARDS: Acute respiratory distress 
syndromeDepression, anxiety and stress scale (DASS); CDC:Centers for Disease Control and Prevention; ssRNA: 
Single-stranded ribonucleic acid; DASS; Depression, anxiety, and stress scale; IES-R: Impact of Event Scale-Revise 
Introduction 
COVID-19 is a global public health emergency originating from Wuhan city (30 January 2020, Hubei province), 
China, and has been rapidly transmitted to over 200 countries around the world [1-3]. The World Health 
Organization (WHO) confirmed the first case reported a month later on 31 December 2020 [4]. Collaborative 
efforts and clinical solidarity studies are underway worldwide to detect new viruses that cause rapidly spreading 
diseases, SARS-CoV-2 (denomination 2019- nCoV) and to monitor and develop new therapies with a proven safety 
profile to prevent outbreak [5-8]. Coronavirus is positive sense and single strand RNA enveloped by outer three 
structural proteins, i.e. membrane (M), spike (S) and envelope (E) [9]. The members of the family Coronaviridae 
infect an extensive collection of animals. The total amount of RNA present inside the virus varies between 26–32 
kb. Family coronavirids are categorized into subfamily alpha, beta, gamma, and delta coronaviruses that are 
present in animals and humans. Betacoronavirus may cause severe respiratory illness for other SARS and MERS 
endemics [10-12]. In humans, they have caused mild respiratory infections such as the common cold and cough. 
Clinical manifestations associated with COVID-19 are fever, cough, indigestion, and pneumonia [13]. Acute 
respiratory distress syndrome (ARDS) is the main factor of respiratory failure and severe mortality. The similarity in 
terms of viral load between asymptomatic and symptomatic patients contributes to the onset of symptoms as 
super-spreaders [14]. The most common preexisting comorbidities are diabetes, cardiovascular disease (CVD), 
digestion, cerebrospinal, hypertension, hepatitis-2, cancer, rheumatoid arthritis and neurological debility (Table 1) 
[15]. Current clinical studies confirm that COVID-19 infection is not confined to respiratory tract but also invading 
other organ such as central nervous system (CNS) producing neurological impairment [16]. However, retrospective 
clinical, laboratory, and computed tomography studies have suggested vertical intrauterine transmission of COVID-
19 in from infected pregnant women to fetus [17]. Currently limited data on vertical transmission from mother to 
fetus, no evidence of intrauterine transmission [9,18]. Due to the COVID-19 infection, there is a possibility of 
developing the congenital disease in the fetus. Further, the prevalence of COVID-19 and severe disease associated 
with sex and smoking correlate with high expression of the ACE2 receptor [19- 22]. Some studies, however, 
recommend that active cigarette smoking is not connected with COVID-19 disease severity [23]. However, Brake et 
al suggested that smoking increased the binding of the ACE2 receptor to COVID-19 and more mortality in the 
Chinese city of Wuhan, where men have a high rate of smoking [24-26]. Clinical trials are running into protective 
and curative effect of antiviral agents such as antimalarial drugs (chloroquine and sister molecule 
hydroxychloroquine), remdesivir, Lopinavir/ritonavir,Favipiravir, Ribavirin, angiotensin convertin enzyme (ACE2) 
blockers, Tocilizumab, Sarilumab,convalescent plasma therapy, Human monoclonal antibody, mRNA-1273 vaccine, 
mesenchymal stem cells, traditional Chinese medicine, indian traditional medicine, natural products and dietary 
supplements, vitamins, immunoenhancers such as IFN-alpha and zinc and many others sumarised in table-2. 
Chloroquine phosphate has shown efficient in treating COVID-19 infection with acceptable safety standards in 
multicenter clinical trials [27]. Immunotargeting of epitopes provide new paradigm of therapy against coronavirus. 
Nearly, 120 epitopes present on B and T cells, determined by considering high similarity between SARS-CoV-2 and 
SARS-CoV [28]. Immune system hyperactivity may occur in COVID-19 patient that may be the leading cause of 
hyperinflammation (cytokine storm nomenclature) and macrophage activation syndrome (MAS). MAS is most 
often outside the lung and is an activation of the intravascular coagulation cascade for overweight fever, lymph 
enlargement, hepatosplenomegaly, anaemia, cytopenius, liver function disorders, and inflammation [29] 
Hyperinflammation therapy is the critical need to decrease mortalities [30]. Hyperinflammatory syndrome is a 
secondary hemophagocytic lymphohistiocytosis (SHLH), characterized by malignant hypercytosis and MAS with 
multiorgan failure [31]. Current theory deals on the progress of new therapies, including antivirals and vaccines 
with proven safety profiles. 
Plant  Molecules Research outcomes  Reference
Nigella Sativa Nigellidine and α- Hederin  Potential treatment to COVID1-9 and further needed to explore clinical trial.  [135]  
Digitalis 
purpurea Digitoxigenin  
Inhibitors of COVID-19 based on energy of 






Polysaccharide G1-4A, Cordifolioside A 
and Syringing 
Earlier reports on immunomodulatory effect 
(MAPK, cAMP, PI3K-AKT, NF-kB, interleukin, 





Aloeride Interaction of viral enzyme and envelope. Clinical trial necessary to confirm activity.   [138, 139] 
Curcuma longa  Demethoxycurcumin Potential inhibitor of COVID-19 causing virus [140] 
Withania 
somnifera Withanone 
Prophylaxis (Antiviral, immune enhancing and 
vascular integrity) and management (Pyrexia, 




Better pharmacokinetic and highest binding 
affinities with enzyme of COVID-19.  [140]  
Ocimum 
sanctum 
Apigenin, Baicalein, Chrysin, Luteolin, 
Scutellarein, Tangeritin, Wogonin and 
6-Hydroxyflavone 
Targeting RdRp enzyme of SARS-CoV.  [143]  
Cannabis sativa Cannabidiol Prevent infection with SARS-CoV-2. Alter the expression of ACE2 and TMPRSS2.  [144]  
Withania 
somnifera Withanolide D and  Withaferin A  
Good binding affinity and best ADME 
properties and  potential inhibitors against 
COVID-19 Main Protease,  
[145]  
Piper nigrum Piperine  Enhance immune system as a prophylactic measure against COVID-19. [146]  
Table: 1: Potential role of natural plant-based product against COVID-19 infections. 
Comorbid 
condition Patients  (N)  and Country 
Key points and correlation of patients with COVID-19 
with comorbid effect references
Cancer (N=1035)  Kirkland, WA, USA 
30th-day mortality COVID-19 cancer patients were 
elevated and associated with general risk factors. Long-
term follow-up is needed to better understand the effect 
of COVID-19 on outcomes in cancer patients. 
[119]  
Diabetes  (N=16,003)  for 33 studies COVID-19 diabetic patients have twice the mortality and severity rate than non-diabetics. [147]  
Hepatitis B (N=1,099)  
The study confirms that COVID-19 patients are more 
likely to be infected with hepatitis B. More severity of 
cases is reported in patients with hepatitis B.   
[148]  
Comorbid 
condition Patients  (N)  and Country 
Key points and correlation of patients with COVID-19 
with comorbid effect references
CVD Wuhan, China  
CVD is an important risk factor for rapid progression and 
an unfavorable prognosis for COVID-19. To prevent rapid 
degeneration more intensive care should be under taken 
in patients with CVD.  
[115]  
Digestive (N=91), Wuhan, China. 
Gastrointestinal symptoms during this disease and 
continue to release viruses in the stool, despite 
respiratory samples being negative. 
[149]  
Neurological 
impairment  (N=214), Wuhan, China 
Neurological symptoms were observed in 36.4% of 
patients with COVID-19 and common in patients with 
severe infection (45.5%) based on their respiratory 
status, which included acute cerebrovascular events, 




(N=51) patients with a mean 
age of 64 ± 15 years, 57% 
men. Madrid, Spain 
Mortality rate of COVID-19 patients are higher in Chronic 
kidney disease. [151]  
Liver injury (N=41), Wuhan, China.  
Progressive respiratory failure and massive alveolar 
degenerations is fatal for COVID-19 infection and more 
mortality (3%).  
[152]  
Rheumatoid 
arthritis (N=231) Ankara 
COVID-19 resembling rheumatic diseases, the possible 
reasons for why children are affected less severely.  [153]  
Smoking  (N=1099) Paris, France  Smoking persons are higher risk of COVID-19 infections.  [26] 
Table 2: Comorbid statuses on COVID-19 infection summarized. 
This review summarizes the COVID-19 hypothesis background, pathogenesis, method of transmission, comorbid 
status, current treatment, and clinical studies of cytokine storms. 
Historical Background 
The corona viruses (CoVs) were first identified in 1930 [32] in domesticated chickens called avian infectious 
bronchitis virus (IBV), and first human coronaviruses (HCoV) were identified by Tyrr and Bynoe named B814 in late 
1960 However, they were unable to grow in tissue culture. Further, Hamre and Procknow were able to grow this 
virus in tissue culture called 229E and lipid containing coat of this virus majorly involved for infection in human. 
Meantime McIntosh et al were successfully grow in organ culture and given the name “OC”. Furthermore, electron 
microscopy on fluids from organ cultures infected with B814 demonstrates that B814 resembled like infectious 
bronchitis virus (IBV) of chicken. Other virus such as 229E and OC also showed similar morphology [33]. 
Further, in 2001, Canadian scientist observed flu like symptoms in 500 patients, among 17 to18 were infected with 
Corona virus confirmed by virological analyses through PCR. Until, 2002, corona virus was treated as simple and 
nonfatal to human. In 2002-2003, evidence suggests that corona virus transmitted in human via civet cat, and 8422 
people suffered from this virus with 11% mortality rate. Lately, this virus identified as severe acute respiratory 
syndrome (SARS) virus [34]. Next, in 2003, several countries such as USA, Hong Kong, Singapore, Thailand, Vietnam 
and Taiwan have reported that more than 100 patients die due to SARS. Another study of Hong Kong was 
confirmed 50 patients of SARS while 30 of them were confirmed as corona virus infected [35]. In 2004, World 
health organization (WHO) and centers for disease control and prevention (CDCP) announced as state emergency. 
Recent, in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) bat origin emerged in Saudi Arabia 
with camel as intermediate host and reports were presented 2494 infected patients and 858 deaths [36-39]. In 
December 2019, cases of unknown etiology of pneumonia first reported in Wuhan, Hubei Province of china caused 
by a corona virus, named 2019 novel corona virus (2019-nCoV). Further, WHO gave the name COVID-19” on 11 
February 2020 [40]. 
Epidemiology, Characteristic, Pathogenesis, and Transmission of COVID-19 
Epidemiology 
COVID-19 was originated in animal market of Wuhan city, Hubei Province of China and represented a major 
transporter hub for virus with unknow etiology of pneumonia [PMC7166041]. COVID-19 cases were first confirmed 
in Haunan seafood market by etiological investigation of respiratory samples of patients. Without delaying, China 
notified the outbreak to WHO and COVID-19 outbreak was declared as public health emergency of international 
concern on Jan30, 2020 [41]. Furthermore, sequencing results evident that COVID-19 has ˃95% homology with bat 
coronavirus and >70% similarity with the SARS-CoV. Nonetheless, environmental sample from Haunan market also 
tested COVID-19 positive, implying that virus originated from Haunan market [42]. While Chinese government 
thinking and how to curb the outbreak, withing short period of time number of corona case increases 
exponentially without having any exposure to Haunan Market, confirming that virus transmission human to human 
occurring. The first fatal case was reported in 11th January 2020 [1,5]. Moreover, immense migration of people 
during Chinese New Year celebration put world on high risk for epidemic. Subsequently, the infection move rapidly 
from China and enclasp Thailand, Japan and South Korea [43]. Cases of COVID-19 reported in healthcare workers 
on 20th January 2020. Soon after, on 23rd Jan 2020, Wuhan was lockdown [44] and extended to other cities of 
China to curb the human to human transmission [45].Seeing the seriousness of COVID-19 many country including 
India put screening mechanisms to identify the symptomatic people returning from china and placed them in 
quarantine if they are suspected for COVID-19 [46]. Meanwhile, WHO worked with International Air Transport 
Association (IATA) and issued guideline for cabin crew and airport worker for preventive measure. Immediately it 
was apparent that the infection could be transmitted by asymptomatic people and before onset of symptoms. 
Therefore, several countries evacuated their citizen from Wuhan through special flights and returning from china, 
placed all people symptomatic in isolation for 14 days and tested for COVID-19. Cases continue to increase 
exponentially and several studies reported an epidemic doubling time of 1.8 day [47]. 12th Feb 2020, china issued 
guideline for confirmed cases and include patient for molecular test such as RT-PCR (reverse transcriptase-
polymerase chain reaction) but clinical, radiological and epidemiological features of COVID-19 outbreak leading to 
increase up to 15000 in single day(https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-
reports).This virus is a very contagious and spread all over world in short time [1,4,48]. Around 6,354,624 cases of 
COVID-19 and 376796 deaths have been reported till June 01,202 (https://www.worldometers.info/coronavirus). 
Virus was replicated in ciliated epithelium that caused cellular damage at infection site. According to a study 
reported in 2019, Angiotensin converting enzyme 2 (ACE.2), a membrane receptor exopeptidase used by corona 
virus in entry to human cells [49-51]. Virus transmission routes were represented in Figure 1. 
 
Figure 1: Representative photomicrograph of histopathological features in pulmonary necropsies. 
 
Characteristic of COVID-19 
COVID-19 is an enveloped non-segmented positive-sense-singlestranded RNA virus (+ssRNA) and its diameter 
approximately 60-140nm with crown shaped appearance [52-55]. The corona family classified into four genera of 
CoVs, namely alpha-, beta-, gamma- and delta-coronavirus. Among them, alpha- and beta-CoV are able to infect 
mammals, while gamma- and delta-CoV tend to infect birds [54]. Currently, seven human CoVs (HCoVs) are 
identified to infect the human. These are HCoV-OC43, and HCoV-HKU1 (beta-CoVs of the A lineage); HCoV-229E, 
and HCoV-NL63 (alpha-CoVs). Other human CoVs such as SARS-CoV, SARS-CoV-2, and MERS-CoV (beta-CoVs of the 
B and C lineage). COVID-19 showed 94.6 % amino acid similarities with SARS-COV and its genome has 96% 
homology with SARS-like coronavirus (Bat-CoV (RaTG13) [56].This suggest that COVID-19 belongs to beta-CoVs 
family and its RNA genome contains 29891 nucleotides, encoding for 9860 amino acids. Evidence showed 2% of 
the human population are healthy carriers of a CoV and these viruses are responsible for about 5% to 10% of acute 
respiratory infections [55]. Its genome encode has four major structural proteins; (1) the nucleocapsid protein (N), 
(2) the spike protein (S), (3) envelop protein (E), and (4) membrane glycoprotein (M) [56]. Spike is composed of a 
Transmembrane trimetric glycoprotein protruding from the viral surface, which determines the diversity of corona 
viruses and host tropism. Spike comprises two functional subunits; S1 subunit is responsible for binding to the host 
cell receptor and S2 subunit is for the fusion of the viral and cellular membranes [57]. 
Pathogenesis and transmission of COVID-19 
The COVID-19 infection could be asymptomatic or symptomatic and asymptomatic infections pay more attention 
how to control the spreading of virus. The symptoms of COVID-19 infection appear approximately 5.2 day of 
incubation. The COVID-19 symptoms to death range vary between 6 to 41 days with a median of 14 days. However, 
this range depends on the age of the patient and the underlying diseases. [41]. The most common clinical 
manifestation at onset of COVID-19 infections includes fever, cough, fatigue, dyspnea, headache, hemoptysis, 
diarrhea, lymphopenia, and radiographic evidence of pneumonia. Besides, acute respiratory distress syndrome 
(ARDS), RNAaemia, acute cardiac and Kidney injury were also reported [5, 58,59]. Currently, several countries 
normally using chest CT scan in the identification of asymptomatic infections [60]. Most of the symptoms of 
COVID-19 like SARS-CoV and MERS-CoV infections. Although clinical manifestation of COVID-19 poorly understood, 
hence studied on SARS-CoV and MERS-CoV provides us a lot of clinical pathogenic information which can help in 
recognition of COVID-19 [61]. Ocular infection of COVID-19 is not studied well but reports indicated that virus can 
cause ocular infection in various wild animals [62]. Case studies on women suggested that there is no evidence 
transplacental transmission of COVID-19 [63]. Clinical manifestation of COVID-19 in children are different than 
adult, even though they show milder disease and low death rate than adult [64]. However, some studies suggested 
they need more attention [65]. Nonetheless, frontline health worker (Otolaryngologists) are on major risk of 
COVID-19 infection [66]. The report suggests that airborne droplets require caution for healthcare professionals 
who treat COVID-19 and need safety and handling while maintaining a distance greater than 2 meters [9,67,68]. 
However, still global scientific community are behind to understand the exact molecular pathophysiology of 
COVID-19 and might study on animal and clinical trial offer promising avenue for treatment of COVID-19. 
It is evidence that COVID-19 has potential to hijack the human angiotensin- converting enzyme-2 (ACE-2) receptor 
to infect the humans, as like SARS-CoV. ACE-2 is a type-1 integral membrane glycoprotein that mainly expressed in 
lung, heart, kidney, and intestine [9]. ACE-2 is a master regulator of RAS by converting angiotensin (Ang) I and II 
into Ang 1-9 and Ang1-7, respectively [69]. Full length ACE2 contains N-terminal peptidase domain (PD) and a C 
terminal Collectrin-like domain (CLD) that ends with a single transmembrane helix and a ~40-residue intracellular 
segment [70]. Studies on SARSCoV, demonstrated that S protein (spike glycoprotein) on CoV surface exist in a 
metastable pre-fusion confirmation, mediates receptor recognition and membrane fusion (Figure 1). Infection 
triggers the cleavage of trimeric S proteins into S1 and S2 subunits, receptor binding domain (RBD) of S1 directly 
binds to the peptidase domain (PD) of ACE-2, and S2 subunits facilitate the membrane fusion [70]. In the whole 
process of virus entry into cells, the spike protein (S) of virus must prime by the protease called TMPRSS2 [71]. 
Recent finding showed S protein of COVID-19 has higher affinity than SARS-CoV in binding to ACE-2 receptor [72]. 
Once virus enters into host cells, uncoats the genome and followed by the transcription and translational process. 
Cytoplasmic membrane is a major site for COVID-19 genome replication and transcription. The COVID-19 replicase 
complex consists of a maximum of 16 viral subunits and various cellular proteins. Besides, it also has RNA-
dependent RNA polymerase, RNA helicase which are common to RNA viruses; however, it has unique machinery 
which is not common to RNA viruses such as putative sequence-specific endoribonuclease, 3′-to-5′ 
exoribonuclease, 2′- O- ribose methyltransferase, ADP ribose 1′-phosphatase, and cyclic phosphodiesterase 
activities. Finally, the viral genomic RNA packed into mature particle at the Endoplasmic-Golgi intermediate 
complex and transported to the cell surface for their released via exocytosis [73]. 
Current pharmacological treatment status for COVID-19 
Today, entire world has been suffering from a challenge against COVID-19. Till date, 27,997,526 corona virus cases 
have been reported, out of which 907,029 patients died all over the world and 1,960,472 patients recovered. 
Unfortunately, no drug or vaccine has yet been approved to treat human against COVID19. Several options can be 
envisaged to control or prevent emerging infections of COVID-19, including vaccines, monoclonal antibodies, 
interferon therapies and small-molecule drugs. Initial analyses of genomic sequences from COVID-19 indicate that 
the catalytic sites of the four COVID-19 enzymes share a high level of sequence similarity to the corresponding 
SARS and MERS enzymes [36]. Although there are no specific targeted therapies for COVID-19 patients, there are 
some potential therapeutic candidates in development for COVID-19 based on clinical trials (Figure 2). 
Figure 2: Representative photomicrograph of histopathological features in pulmonary necropsies. 
 
Antiviral drugs 
Remdesivir: Remdesivir, a nucleotide prodrug, originally developed to control the Ebola virus [74] that 
subsequently demonstrates its efficacy in inhibiting corona viruses such as SARSCoV and MERS-CoV in vitro [75]. 
Treatment with intravenous remdesivir successfully improved the clinical state of the first U.S. COVID-19 patient 
[76] .Remdesivir is now being tested in several clinical trials designed to evaluate its efficacy and safety for the 
treatment of COVID-19. The treatment of remdesivir to critically ill patients reduced the mortality rate. 
Additionally, it was also tested in combination with chloroquine and found to be effective against COVID-19. 
However, efficacy of the drug to treat COVID-19 patients need to be further explored. 
lopinavir/ritonavir: lopinavir/ritonavir (lpv-r), a nucleoside analogue, is a human immunodeficiency virus (hiv)-
specific protease inhibitor that serves as first-line therapy for hiv [77]. lpv-r has been reported to have in vitro 
inhibitory activity against sars-cov [78], and combination therapy of lpv-r and ribavirin provided favorable results in 
treating patients with sars [78]. triple combination therapy with lpv-r, ribavirin and ifn-α has shown clinical 
effectiveness for mers [79]. monotherapy with lpv-r did not provide protection against covid-19 patients [80]. 
however, combination of lpv-r and arbidol improves the pulmonary computed tomography images [81]. 
collectively, the combination therapy of lpv-r and other antiviral agents in early stages of covid-19 infection might 
be promising strategy for treating covid-19. 
favipiravir: favipiravir also known as avigan is actually approved to treat influenza in japan and china and is under 
investigation for use in covid-19. it interferes with viral genome replication. clinical trial in wuhan based on 
conventional therapy demonstrated that favipiravir has higher efficacy than arbidol in terms of the 7-day recovery 
rate and duration of symptom attenuation in patients with moderate covid-19 infection [82]. 
ribavirin: ribavirin is an approved nucleoside analogue used to treat sars-cov patients [83, 84]. this drug shows 
significant effect in combination with a nucleotide analogue sofosbuvir which is under clinical trial. the wide 
availability and low cost of ribavirin support its use for the treatment of covid-19 infection. 
Antimalarial drugs 
Chloroquine and hydroxychloroquine: Chloroquine (CQ) and hydroxychloroquine (HCQ) are the class of quinoline 
derivatives and widely used to treat malaria caused by Plasmodium vivax, P. malariae, and P. ovale. It is obtained 
from cinchona bark and also used to treat autoimmune disease apart from malaria. CQ and HCQ, a less toxic 
derivative of CQ, has antiviral activity against SARS-CoV and also demonstrated anti-SARS-CoV-2 activity . CQ and 
HCQ can attenuate “cytokine storms” by decreasing cytokine production due to its immunomodulatory effects, 
which is high in COVID-19 infection [5]. The combination of CQ/HCQ with Remdesivir or second generation 
macrolide such as Azithromycin produces beneficial effects against COVID-19 infection [37,85]. However, there is a 
report of increased ventricular arrhythmias and decreased survival rate of patients infected with COVID-19 after 
the treatment with CQ/HCQ either alone or in combination with macrolide [86]. A number of clinical trials are 
underway to evaluate the efficacy of CQ/HCQ against COVID-19. CQ/ HCQ are promising approach to treat COVID-
19 due to its low cost and easy availability. The studies and clinical trials on this drug are going on and needs a 
further research. 
Convalescent Plasma Therapy 
The plasma from infected people who have recovered from disease is called convalescent plasma. Patients who 
have recovered from COVID-19 possess antibodies to fight against infection. Plasma therapy provides a great 
degree of protection for recipients affected by the emerging virus [87]. This therapy is considered to be helpful for 
those patients with COVID-19 who does not respond to other treatments. Recently, the efficacy of convalescent 
plasma in controlling SARS-CoV-2 has been reported by Chinese researchers [88]. While convalescent plasma 
therapy is promising, it is not safe as a treatment option for COVID-19. Thus, the safety and efficacy of use of 
convalescent plasma to treat COVID-19 in clinical trials require more research. 
Spike Protein-Angiotensin Converting enzyme 2 blockers: 
Angiotensin converting enzyme 2 (ACE2), negative regulator of the renin angiotensin system (RAS), is widely 
expressed in lung tissue, blood vessels, intestine, heart, liver, kidney and brain. ACE2 is also a functional receptor 
of SARS-CoV [89] and SARS-CoV-2 [8]. The spike protein of SARS-CoV and SARS-CoV-2 binds to the host ACE2 
receptor and then enters target cells. Thus, blocking spike protein binding to ACE2 might offer some protection 
against SARS-CoV-2 infection. RAS and ACE2 inhibitors are widely used to treat cardiovascular disease. The 
selective ACE2 inhibitor DX600 might show beneficial results against SARS-CoV-2 infections [90]. In a report, 
circulating ACE2 protein when administered intravenously produced significant blockade of initial stages of SARS-
CoV-2 viral entry and infections by preventing the binding of viral spike protein onto host cell surface ACE2. 
However, there has been no definite evidence on whether taking ACE2 inhibitors is effective for COVID-19 infected 
patients. 
Human monoclonal antibody against COVID-19 
Monoclonal antibodies are currently used for diagnostic and therapeutic purposes. FDA has approved numerous 
monoclonal antibodies to treat diseases such as cancer and autoimmune disorders. Several monoclonal antibodies 
such as bevacizumab, tocilizumab, and meplazumab are used to treat SARS-CoV-2 infections. 
Tocilizumab and sarilumab: Tocilizumab (TCZ) is a monoclonal antibody against IL-6 receptors and used in 
autoimmune diseases such as rheumatoid arthritis and multiple myloma [91]. IL-6 is involved in the activation of 
various immunological and inflammatory mediators, which are responsible for respiratory collapse observed in 
SARS-CoV-2 infected patients. COVID-19 disease severity depends on the increase in pro-inflammatory factors, 
suggesting that increase in cytokine IL-6 is involved in the development of COVID-19. Thus, TCZ has been 
hypothesized to suppress the inflammation in patients infected with SARS-CoV-2. Several clinical trials for TCZ have 
been approved for COVID-19, and the National Health and Family Planning Commission of China has approved the 
treatment with TCZ in patients with elevated IL-6 level. Another IL-6 receptor monoclonal antibody Sarilumab is 
under clinical trials for SARS-CoV-2. Like TCZ, it is also used in the treatment of rheumatoid arthritis and it 
suppresses the IL6 receptor mediated inflammation [92]. According to a report from Regeneron Pharmaceuticals, a 
phase Ⅱ/III clinical trial for sarilumab has been conducted to assess its therapeutic effects in patients with severe 
COVID-19 infection. The potential therapeutic role of Sarilumab in COVID- 19 needs to be further confirmed in 
clinical conditions. 
Bevacizumab: Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that competes 
with VEGF receptors on the surface of endothelial cells for VEGF binding, and thus inhibiting the effects caused by 
binding VEGF to its receptors. Previous reports have shown that plasma VEGF levels markedly increase in patients 
with Acute respiratory distress syndrome (ARDS) [93]. ARDS is a common complication in patients suffering from 
COVID-19 and bevacizumab might be a potential anti-ARDS therapeutic approach to treat the disease. 
Bevacizumab is therefore likely to be a promising therapy against COVID-19. 
Vaccines for COVID-1 
Currently, there is no vaccine available specific for COVID-19 infection. Most of the institutes and pharmaceutical 
companies areworking on a SARS-CoV-2 vaccine. One such vaccine is mRNA-1273, which is developed by scientists 
of National Institute of Allergy and Infectious Disease along with Moderna. This vaccine delivers the antigen into 
human cells to elicit SARSCoV-2-specific neutralizing antibodies thereby protecting against COVID-19 infection. 
mRNA-1273 was the first vaccine to be tested in a clinical trial against COVID-19. Similar type mRNA vaccine 
BNT162 was developed by BioNTech and Pfizer company to treat COVID-19 infection, which is under the clinical 
trials. Another, newly developed, potentially effective vaccine is PittCoVacc developed by University of Pittsburgh 
School of Medicine scientists [94]. PittCoVacc generates SARSCoV-2 specific antibodies by using its spike protein. 
This vaccine tends to be safer due to use of microneedle array technique. Several other vaccines are under 
development process. 
Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are multipotent stromal cells, isolated from different mesenchymal tissues. MSCs 
have ability to differentiate into variety of cell types. The mechanisms by which MSCs exert their therapeutic 
effects include immuno-regulation. In case of COVID-19, a number of inflammatory factors that release cytokines 
are being produced by the immune system. MSCs have shown to prevent the release of cytokines by the immune 
system and thereby participate in endogenous repair by reparative properties of the stem cells. MSCs also 
increases the regulatory T cells, and decreases proinflammatory factors such as IL-6 and TNF-α [95,96]. A recent 
case study was reported in China on COVID-19 infected female patient in which 21 days treatment with umbilical 
cord MSCs provides effective results [97]. In another study at Beijing You An Hospital, treatment with MSC 
transplantation significantly improved immune function levels without obvious adverse effects in 7 patients with 
COVID-19 [98]. Thus, MSC therapy might be one of the most promising treatment options for COVID-19. 
Traditional Chinese medicine (TCM) to treat COVID-19 
The Chinese government is heavily promoting traditional medicines as treatments for COVID-19. In China, senior 
government officials and the state media are pushing a range of traditional Chinese medicines as being effective at 
alleviating symptoms and reducing deaths. Several traditional Chinese medicines have been recommended by the 
National Health Commission of China (NHCC) for the prevention and treatment of COVID-19 [99]. These traditional 
medicines have antiinflammatory activity and beneficial immunomodulatory effects for the prevention of viral 
infections including SARS-CoV. A published important report demonstrates that glycyrrhizin, an active constituent 
of liquorice root which is the most frequently used Chinese herb, potently inhibited the replication of SARS virus 
[100]. There are several Chinese herbs formulated in medicine provide beneficial effects in treating patients with 
COVID-19. According to the latest edition of Guideline, several multiple component Chinese herbal products are 
recommended as a preventive measure [34]. For the patients in the medical observation period, Huo Xiang Zheng 
Qi Shui, Lian Hua Qing Wen Capsule, Shu Feng Jie Du Capsule and Jin Hua Qing Gan Granule should be used. In the 
clinical treatment period, patient should be administered with Qing Fei Pai Du Tang, Xi Yan Ping Injection, Xue Bi 
Jing injection, Re Du Ning Injection, Tan Re Qing Injection, Xing Nao Jing Injection. Additionally, in critical situation 
Shen Fu Injection, Sheng Mai Injection, Shen Mai Injection, Su He Xiang Pill and An Gong Niu Huang Pill should be 
administered. 
Indian traditional medicine as a treatment of COVID-19 
In India, the treatment with modern medicine co-exists with indigenous systems of medicine, such as Ayurveda, 
Yoga and Naturopathy, Unani, Siddha and Homeopath. which are extensively used all over the world [101]. In 
response to the COVID-19 crisis, the Indian government released a set of guidelines, developed based on the 
opinion of 16 eminent vaidyas, entitled “Ayurveda’s immunity boosting measures for self-care during the COVID-
19 crisis”, and made them available to the public (https://www.ayush.gov.in/docs/123. pdf). These guidelines 
listed ten measures that were aimed at boosting immunity against infection. Recommendation by Ministry of 
AYUSH, Government of India involved drinking warm water throughout the day and using spices such as turmeric, 
cumin, garlic and coriander in cooking. Ayurvedic treatment are also recommended such as consuming 
chyavanprash, drinking kadha, golden milk, applying coconut or sesame oil in nostrils and rinsing mouth with these 
oils. The relevance of ayurvedic treatment to psychological and immune function during the COVID-19 outbreak 
requires direct experimental testing. The further development of such explanatory models could clarify the 
usefulness of “traditional” medical practices during disease outbreaks, and could facilitate a more synergistic 
interaction between traditional and modern medicine [101]. 
Natural products and dietary supplements 
Our daily diet is rich in lots of vitamins, minerals, carbohydrates, proteins, fats, and lipids. It plays an important role 
in maintaining the body’s homeostasis and build up immunity. Various biological active natural products are also a 
part of our diet and they exert multiple therapeutic effects such as anticancer, antioxidant, anti-inflammatory, 
anti-diabetic, antibacterial, antiviral and antifungal. Since ancient times humans has been dependent on medicinal 
plants for the treatment of various ailments. Active compounds obtained from these plants are widely used as a 
remedy for numerous maladies. Among them widely used natural products are curcumin from turmeric, quercetin 
from onion, withaferin A from Ashwagandha. Curcumin inhibited the pro-inflammatory cytokines such as IL-1β, IL-
6, and TNF-α level and decrease the cytokine storm in Ebola virus infected experimental models [102]. 
Furthermore, curcumin via its protease inhibitor activity also inhibited the SARS-CoV replication and supposed to 
be effective against SARS-CoV-2 infections. Ministry of AYUSH also recommended turmeric in daily diet as a 
treatment measure against COVID-19. Quercetin, widely present in red onions is a plant flavonol having 
pharmaceutical effects against inflammation. It also possesses antiviral activity and inhibited the SARS-CoV entry 
into the host cells. The other natural product withaferin A is isolated from Ashwagandha (Withania somnifera) and 
widely used to treat various diseases such as cancer, fibrosis, and inflammatory disorders. It has shown the 
antiviral activity against Herpes Simplex virus 1 and 2 [103], which may show plausible effects against COVID-19. 
Vitamins 
Several clinical nutritionists have also recommended consuming adequate amounts of Vitamin C and D. Vitamin C 
is water soluble and found in citrus fruits. Vitamin C is widely known as an antioxidant and inhibits aging induced 
oxidative stress. It is also involved in the process of wound healing. Vitamin C is considered as strong immune 
booster, prevent from common cold and protects from wide array of microbial infections [104]. Thus, vitamin C 
might have a promising role to treat COVID-19 patients having lung damage. Vitamin D is associated with the 
regulation of bone metabolism. Increasing evidence show that vitamin D deficiency is associated with increased 
autoimmunity as well as in an increased susceptibility to infection [105]. Vitamin D has an important role in 
modulating immunological functions and reduces the risk of respiratory tract infections due to COVID-19. Vitamin 
D induces antimicrobial peptides which in turn reduce the rate of replication. Several clinical trials of vitamin D in 
patients with COVID-19 are underway. 
Effect of Immuno-enhancers on COVID-19 
Interferons (IFNs) 
Interferons consist of families of numerous type Ⅰ species (IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω) and one 
type Ⅱ species (IFN-γ) [106]. It has been reported that Type Ⅰ IFNs have antiviral activity against SARS-CoV-2 
infection [107,108]. They interfere with viral replication and spread by secretion of cytokines which activate the 
adaptive immunity. In China, administration of 5 million U of IFNα in combination with ribavirin by vapor inhalation 
twice a day has been recommended as a treatment measure against COVID-19 infection [39]. Clinical trials have 
been performed to evaluate the effect of combination of lopinavir/ritonavir and IFNα2b or a combination of 
lopinavir/ritonavir with ribavirin and IFNβ1b on COVID-19 infected patients. IFNβ1 might be a safe and easy 
treatment measure against COVID-19 in the early stages of infection. 
Zinc as a treatment option for COVID-19 
Zinc, an essential micronutrient for human health, plays a key role in the immune system. It is physiologically 
important for the synthesis of enzymes in the body, and also plays a role in protein synthesis, wound healing and 
cell division. Zinc deficiency causes several immune dysfunctions and loss of taste. Interestingly, there are 
numerous reports showing the loss of sense of smell and taste in the early stages of COVID-19 infected people 
[109, 110]. Furthermore, zinc acts as an inhibitor of various other RNA viruses such as SARSCoV and also inhibits 
the replication of corona virus [111]. First clinical trial of intravenous zinc in COVID-19 patients is underway in 
Australia. Furthermore, several clinical trials of the combination of zinc and other candidates such as HCQ in 
patients with COVID-19 are underway. 
Prevalence of Comorbidity and its effect on COVID-19 
The presence of comorbidities has been one of the factors that is constantly found in all cases of COVID-19 deaths 
worldwide (Table 2). The mortality rate was found to be higher in severe cases of COVID-19. It was found to be 
higher in older patients with comorbidities such as hypertension (HTN), chronic obstructive pulmonary disease 
(COPD), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), cerebrovascular disorders and 
cardiovascular disease (CVD) [112, 113]. Huang et al reported the first instance of presence of comorbidity in 27 
COVID-19 patients (66%) in a cohort of 41 patients (median age=49 years; 73% men) who had exposure to animal 
markets in China during COVID-19 outbreak [5]. Another cohort study showed that 32% of the COVID-19 patients 
had underlying comorbidities of which 20% had diabetes and 15% had hypertension [114]. A epidemiological study 
on 99 COVID-19 patients also reported that 40% had cardiovascular and cerebrovascular disease [115]. Another 
study also found HTN, T2DM, CVD and cerebrovascular diseases being the most common comorbidities in their 
cohort of patients with SARS-CoV-2 [116]. Zhou et al. conducted a retrospective study on 191 COVID-19 subjects 
and confirmed that 48% had pre-existing comorbidities in which 30 % had diabetes mellitus and 8% had coronary 
heart disease [7]. Additionally, non-survivors were reported to have an escalated rate of co-morbidities in 
comparison to survivors [117]. T2DM, HTN and coronary heart disease (CHD) are the common comorbidities in 
non-survivors. Acute heart failure (23%) and acute cardiac injury (17%) are most common secondary outcomes in 
COVID-19 patients when compared to primary outcomes such as (59%), respiratory failure (54%), ARDS (31%), and 
acute kidney injury (15%) [7]. These secondary outcomes were found to be higher in non-survivors when 
compared to survivors Moreover, routine laboratory parameters or nonspecific biomarkers such as alanine 
transaminase (ALT), lactate dehydrogenase (LDH), cardiac troponin I (cTnI), ferritin and interleukin-6 (IL-6) were 
elevated in SARSCoV- 2 infection [117]. However, estimation of biomarkers is not adequate in diagnosing 
myocardial injury in SARS-CoV-2 infections, further clinical studies should be addressed based on multimodal 
approach for the diagnosis of extent of cardiac complications. Similarly, COVID-19 patients with cardiovascular 
disease (CVD) as the co-morbidity showed higher mortality rate [118]. Apart from above mentioned reasons, 
myocardial injury was found to be the main cause of death in SARS-CoV-2 infection with higher circulating levels of 
cytokine interleukin (IL-6) and serum levels of C-reactive protein (hsCRP). Cancer as comorbidity has also been 
investigated in COVID‐19 [119]. [109]. A study in cohort of 1590 patients in COVID-19 demonstrated the higher 
risk of 1% for COVID-19 and a high risk of severe events of 39% in cancer patients when compared with those 
without ( 0.29 % and 8%). Severe events included either admission to the intensive care unit undergoing invasive 
ventilation or death [15]. Although, the recent communication also doubts the adequacy of the evidence for a 
concluding the association between COVID-19 and cancer. In this context, it should be emphasized that the 
observed frequency of comorbidities may also reflect transmission dynamic within particular age groups, 
identification of cases or test practices adopted by the hospital during the early stages of the epidemic. 
Paradoxically, the percentage of patients with kidney disease and malignancy such as comorbidity was relatively 
low [119]. COVID-19 can also cause damage to other organs such as the heart, liver, and kidneys, as well as to 
organ systems such as the blood and the immune system [5,120,121]. Patients finally die from multiple organ 
failure, shock, ARDS, heart failure, arrhythmias and kidney failure [114,122]. 
Conclusion and Future Directions 
COVID-19 infection spreading continuously all over world and current treatment is yet to undefined due to 
unknown pathophysiology, mode of transmission and absence of appropriated animal model. However, recently it 
has been reported that golden Syrian hamster resemble COVID-19 with low mortality and promising tool for 
investigating transmission, pathogenesis, treatment and vaccination against SARS-CoV-2 [123]. This review focuses 
on the history of COVID-19, clinical characterization, comorbid effects and information on current therapeutic 
arrangements. Clinical studies of previously known antiviral molecules and natural herbal medicines are required 
to detect COVID-19 treatment. Molecular investigations have suggested that the antiviral potential of bioactive 
therapies targeted at SARS-CoV2-polymerase RdRp reveals an central function in the fight against COVID-19 [124]. 
The library of compounds studied as 6- shogaol, 6-gingerol, ꞵ-sitosterol, piperidine, apigenin, piperine, quercetin, 
α-bisabolol have immune boosting properties to prevent COVID-19 infection [125]. While there are many small 
molecule antioxidants, vitamins, minerals, natural products and supplements that have been proposed as 
alternative treatments for COVID-19, most of them do not validate or lack adequate evidence or multicenter 
clinical trials in research studies or methodology. Unfortunately, COVID-19 is considered an incurable outbreak; 
however, scientists are strictly involved in preventing medical intervention. Under the leadership of WHO, 
solidarity clinical trials were launched to occupied international patients around the world to activate R&D 
blueprints and accelerate diagnostics, vaccines and therapeutics. In all countries below the 35 degree southern 
hemisphere, people with low mortality receive enough sunlight to maintain adequate vitamin D [126-128]. The 
populationbased study confirmed that vitamin C and D high doses supplements could combate the risk of viral 
infection and death. Super-spreaders have been reported during the SARS and MERS epidemics. Although the 
transmission rate of COVID-19 patient currently is 2.2, the number of cases increases rapidly worldwide. However, 
children are not considered super-spreaders and can go back to school [129]. With the advancement of diagnostic 
techniques, potential super-spreaders with asymptomatic cases have been discovered [130]. Currently no anti-
COVID-19 vaccine or preventive treatment undergoes all clinical trials, but some adjunct therapists work (Table 
1).The design and trends of the technology expansion platforms evaluated as nucleic acid (DNA and RNA), virus-
associated particles, amino acids, peptides, replicating and non-replicating viral vectors, recombinant proteins, live 
attenuated viruses and inactivated viruses are approaches to treatment developed against COVID-19. Novel lipid 
nano-particles (LNP) encapsulated mRNA, mRNA-1273 which express S-protein of SARSCoV- 2, provides durability, 
stability and stimulate strong immune response [131,132]. However, other vaccines such as adenovirus type 5 
(Ad5) vector that expresses SARS-CoV S-protein (Ad5-nCoV), DNA plasmid encoding S-protein delivered by 
enhanced electroporation (INO-4800), DCs modified with lentiviral vector expressing synthetic minigene based on 
domains of selected viral proteins; administered with antigen-specific CTLs (LV-SMENP-DC), and a APCs modified 
with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins (Pathogen specific 
aAPC) are in clinical phase I and II from lead developers. Ad5-nCoV is genetically engineered vaccine candidate with 
defect in replication. INO-4800 and its sister candidate INO-4700 are DNA vaccine matched with SARS-CoV-2 and 
MERS-CoV S-protein DNA [133,134]. Finally, strong international level involvement of vaccine developers, 
regulators, policymakers, workers, and government bodies will be necessary to ensure that a promising late stage 
vaccine candidate can be developed. We collectively urge to gather the technical, financial, and scientific support 
necessary to successfully address the COVID-19 pandemic through the Global Immunization Program and provide a 
strong foundation in the future to fight any pandemic. 
Conflict of Interest 
None. 
References 
1. Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 
395:470-473. 
2. WHO (2020) WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China Geneva 2020. 
3. https: //www who int/news-room/detail/30-01-2020-statement-onthe-second-meeting-of-the-international-
health-regulations. 2005. 
4. Zhu N, Zhang D, Wang W, Li X, Yang B, et al.(2019) A Novel Coronavirus from Patients with Pneumonia in China, 
2019. N Engl J Med 382:727-733. 
5. Huang C, Wang Y, Li X, Ren L, Zhao J, et al, (2020). Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. Lancet 395:497-506. 
6. Heymann DL (2020) Data sharing and outbreaks:best practice exemplified. Lancet 395:469-470. 
7. Liu X, Wang XJ (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved 
medicines. J Genet Genomics 47:119-121. 
8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) A pneumonia outbreak associated with a new 
coronavirus of probable bat origin. Nature 579:270-273. 
9. Stroke O, Sacks D, Baxter B, Campbell BCV, Carpenter JS, et al. (2018) Multisociety Consensus Quality 
Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke 
13:612-632. 
10. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, et al. (2015) Middle East respiratory syndrome coronavirus:another 
zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28:465-522. 
11. Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in COVID-19 and potential vaccines:Lessons 
learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38:1-9. 
12. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, et al. (2020) The SARS, MERS and novel coronavirus (COVID-
19) epidemics, the newest and biggest global health threats:what lessons have we learned? Int J Epidemiol 
49:717-726. 
13. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, et al. (2020) Epidemiology, causes, clinical manifestation and 
diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period:a 
scoping review. Infect Dis Poverty 9:29. 
14. Han Y, Yang H (2020) The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-
19)(2020) A Chinese perspective. J Med Virol 92:639-644. 
15. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, et al. (2020) Comorbidity and its impact on 1590 patients with 
COVID-19 in China:a nationwide analysis. Eur Respir J 55: 2000547. 
16. Ogier M, Andeol G, Sagui E, Bo GD (2020) How to Detect and Track Chronic Neurologic Sequelae of Covid-19? 
Use of Auditory Brainstem Responses and Neuroimaging for Long-Term Patient Follow-Up. Brain Behav Immun 
Health 2020:100081. 
17. Chen H, Guo J, Wang C, Luo F, Yu X, et al. (2020) Clinical characteristics and intrauterine vertical transmission 
potential of COVID-19 infection in nine pregnant women:a retrospective review of medical records. Lancet 
395:809-815. 
18. Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K,et al. (2018) Drugging DNA 
repair to target T-ALL cells. Leuk Lymphoma 59:1746-1749. 
19. Vardavas CI, Nikitara K (2020) COVID-19 and smoking:A systematic review of the evidence. Tob Induc Dis 18:20. 
20. Cai H (2020) Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 8:e20. 
21. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, et al. (2020) ACE-2 expression in the small airway 
epithelia of smokers and COPD patients(2020) implications for COVID-19. Eur Respir J 55: 2000688. 
22. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, et al. (2020) The impact of COPD and smoking history on the 
severity of COVID-19:A systemic review and meta-analysis. J Med Virol 15:10. 
23. Lippi G, Henry BM (2020) Active smoking is not associated with severity of coronavirus disease 2019 (COVID-
19). Eur J Intern 75:107-108. 
24. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, et al. (2020) Smoking Upregulates Angiotensin-
Converting Enzyme-2 Receptor:A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin 
Med 9:841. 
25. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, et al. (2020) Prevalence, Severity and 
Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-
Analysis. PLoS One 15:e0233147. 
26. Berlin I, Thomas D, Le Faou AL, Cornuz J (2020) COVID-19 and smoking. Nicotine Tob Res 22:1650-1652 
27. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and 
safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279-283. 
28. Ahmed SF, Quadeer AA, McKay MR (2020) Preliminary Identification of Potential Vaccine Targets for the 
COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 12:254. 
29. McGonagle D, Sharif K, O'Regan A, Bridgewood C (2020) Interleukin-6 use in COVID-19 pneumonia related 
macrophage activation syndrome. Autoimmun rev 2020: 102537. 
30. Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Correction to Clinical predictors of mortality due to COVID-19 
based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:1294-1297. 
31. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS (2020) COVID-19 consider cytokine storm syndromes 
and immunosuppression. Lancet 395:1033-1034. 
32. Estola T (1970) Coronaviruses, a new group of animal RNA viruses. Avian Dis 14:330-336. 
33. Kahn JS, McIntosh K (2020) History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24:S223-
227. 
34. Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. 
Travel Med Infect Dis 34:101615. 
35. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PRv (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and coronavirus disease-2019 (COVID-19):The epidemic and the challenges. Int J Antimicrob Agents 
55:105924. 
36. Morse JS, Lalonde T, Xu S, Liu WR (2020) Learning from the Past:Possible Urgent Prevention and Treatment 
Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem 21:730-738. 
37. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently 
emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269-271. 
38. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A (2006) New insights into the antiviral effects of 
chloroquine. Lancet Infect Dis 6: 67-69. 
39. Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 
14:58-60. 
40. Deng SQ, Peng HJ (2020) Characteristics of and Public Health Responses to the Coronavirus Disease 2019 
Outbreak in China. J Clin Med 9:575 
41. Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) 
outbreak. J Autoimmun 109:102433. 
42. Singhal T (2020) A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 87:281-286. 
43. Schwartz DA, Graham AL (2020) Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-
nCoV Infecting Pregnant Women:Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses 
12:194. 
44. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (2020) Coronavirus Disease 2019 (COVID-19):A 
Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol 215: 87-93. 
45. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, et al. (2020) Transmission of 2019-nCoV Infection from 
an Asymptomatic Contact in Germany. N Engl J Med 382:970-971. 
46. La VP, Pham TH, Ho MT, Nguyen MH, P Nguyen KL, et al. (2020) Policy Response, Social Media and Science 
Journalism for the Sustainability of the Public Health System Amid the COVID-19 Outbreak: The Vietnam 
Lessons. Sustainability 12:2931. 
47. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel 
Coronavirus-Infected Pneumonia. N Engl J Med 382:1199-1207. 
48. Sun P, Lu X, Xu C, Sun W, Pan B (2020) Understanding of COVID-19 based on current evidence. J Med Virol 
92:548-551. 
49. Woo PC, Lau SK, Huang Y, Yuen KY (2020) Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol 
Med 234:1117-1127. 
50. de Souza Luna LK, Heiser V, Regamey N, Panning M, Drexler JF, et al. (2007) Generic detection of 
coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and 
nonfluorescent low-density microarray. J Clin Microbiol 45:1049-1052. 
51. Letko MC, Munster V (2020) Functional assessment of cell entry and receptor usage for lineage B β-
coronaviruses, including 2019-nCoV. bioRxiv 2020. 
52. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, et al. (2020) World Health Organization declares global 
emergency(2020) A review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71-76 
53. Wang L, Wang Y, Ye D, Liu Q (2020) Review of the 2019 novel coronavirus (SARS-CoV-2) based on current 
evidence. Int J Antimicrob Agents 55: 105948 
54. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, et al. (2020) The origin, transmission and clinical therapies on 
coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 7:11 
55. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, Evaluation and Treatment 
Coronavirus (COVID-19). In StatPearls. Treasure Island. 
56. Yang P, Wang X (2020) COVID-19: a new challenge for human beings. Cell Mol Immunol 17:555-557 
57. Delmas B, Laude H (1990) Assembly of coronavirus spike protein into trimers and its role in epitope expression. 
J Virol 64:5367-5375. 
58. Lima C (2020) Information about the new coronavirus disease (COVID-19). Radiol Bras 53:V-VI. 
59. Hamid S, Mir MY, Rohela GK (2020) Novel coronavirus disease (COVID-19): a pandemic (epidemiology, 
pathogenesis and potential therapeutics). New Microbes New Infect 35:100679 
60. Meng H, Xiong R, He R, Lin W, Hao B, et al. (2020) CT imaging and clinical course of asymptomatic cases with 
COVID-19 pneumonia at admission in Wuhan, China. J Infect 2020. 
61. Li X, Geng M, Peng Y, Meng L, Lu S (2020) Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm 
Anal 10:102-108. 
62. Seah I, Agrawal R (2020) Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of 
Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm 28:391-395 
63. Chen Y, Peng H, Wang L, Zhao Y, Zeng L, et al. (2020) Infants Born to Mothers With a New Coronavirus (COVID-
19). Front Pediatr 8:104 
64. Ludvigsson JF (2020) Systematic review of COVID-19 in children shows milder cases and a better prognosis 
than adults. Acta Paediatr 109:1088-1095. 
65. Lin J, Duan J, Tan T, Fu Z, Dai J (2020) The isolation period should be longer:Lesson from a child infected with 
SARS-CoV-2 in Chongqing, China. Pediatr Pulmonol 55:E6-E9 
66. Vukkadala N, Qian ZJ, Holsinger FC, Patel ZM, Rosenthal E (2020) COVID-19 and the Otolaryngologist: 
Preliminary Evidence-Based Review. Laryngoscope 2020. 
67. Cheung JC, Ho LT, Cheng JV, Cham EYK, Lam KN (2020) Staff safety during emergency airway management for 
COVID-19 in Hong Kong. Lancet Respir Med 8:e19. 
68. Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, et al. (2020) Airborne Transmission Route of COVID-
19:Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough. Int J Environ Res Public Health 
17:2932. 
69. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, et al. (2020) Angiotensin-Converting Enzyme 2:SARS-
CoV-2 Receptor and Regulator of the Renin-Angiotensin System:Celebrating the 20th Anniversary of the 
Discovery of ACE2. Circ Res 126:1456-1474. 
70. Yan R, Zhang Y, Li Y, Xia L, Guo Y, et al. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length 
human ACE2. Science 367:1444-1448 
71. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, et al. (2011) A transmembrane serine protease is 
linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 85:873-
882 
72. Zhai X, Sun J, Yan Z, Zhang J, Zhao J, et al. (2020) Comparison of SARS-CoV-2 spike protein binding to ACE2 
receptors from human, pets, farm animals, and putative intermediate hosts. J Virol 94:e100831. 
73. Garoff H, Hewson R, Opstelten DJ (1998) Virus maturation by budding. Microbiol Mol Biol Rev 62:1171-1190. 
74. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, et al. (2017) Discovery and Synthesis of a Phosphoramidate 
Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and 
Emerging Viruses. J Med Chem 60:1648-1661. 
75. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, et al. (2017) Broad-spectrum antiviral GS-5734 
inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653. 
76. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, et al. (2020) First Case of 2019 Novel Coronavirus in 
the United States. N Engl J Med 382:929-936. 
77. Barragan P, Podzamczer D (2008) Lopinavir/ritonavir:a protease inhibitor for HIV-1 treatment. Expert Opin 
Pharmacother 9:2363-2375. 
78. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, et al. (2004) Role of lopinavir/ritonavir in the treatment of 
SARS(2020) initial virological and clinical findings. Thorax 59:252-256. 
79. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC (2016) Combination therapy with lopinavir/ritonavir, ribavirin and 
interferon-alpha for Middle East respiratory syndrome. Antivir Ther 21:455-459 
80. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 
Severe Covid-19. N Engl J Med 382:1787-1799. 
81. Deng L, Li C, Zeng Q, Liu X, Li X, et al. (2020) Arbidol combined with LPV/r versus LPV/r alone against Corona 
Virus Disease 2019:A retrospective cohort study. J Infect 81:e1-e5 
82. Chen C, Huang J, Cheng Z, Wu J, Chen S, et al. (2020) Favipiravir versus arbidol for COVID-19: a randomized 
clinical trial. MedRxiv 17:1-7. 
83. Rothan HA, Bahrani H, Mohamed Z, Teoh TC, Shankar EM (2015) A combination of doxycycline and ribavirin 
alleviated chikungunya infection. PLoS One 10:e0126360. 
84. Koren G, King S, Knowles S, Phillips E (2003) Ribavirin in the treatment of SARS:A new trick for an old drug? 
CMAJ 168:1289-1292. 
85. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, et al. (2020) Hydroxychloroquine and azithromycin as a 
treatment of COVID-19; results of an open-label non-randomized clinical trial. Int J Antimicrob Agent 
56:105949. 
86. Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a 
macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 20. 
87. Dodd RY (2012) Emerging pathogens and their implications for the blood supply and transfusion transmitted 
infections. Br J Haematol 159:135-142. 
88. Roback JD, Guarner J (2020) Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA 
323:1562-1563. 
89. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, et al. (2003) Angiotensin-converting enzyme 2 is a functional 
receptor for the SARS coronavirus. Nature 426:450-454 
90. Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, et al. (2003) Novel peptide inhibitors of angiotensin-
converting enzyme 2. J Biol Chem 278:15532-15540 
91. Scott LJ (2017) Tocilizumab:A Review in Rheumatoid Arthritis. Drugs 77:1865-1879. 
92. Pelechas E, Voulgari PV, Drosos AA (2019) Clinical evaluation of the safety, efficacy and tolerability of 
sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 15:1073-1079. 
93. Thickett DR, Armstrong L, Christie SJ, Millar AB (2001) Vascular endothelial growth factor may contribute to 
increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 164:1601-
1605. 
94. Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, et al. (2020) Microneedle array delivered recombinant 
coronavirus vaccines(2020) Immunogenicity and rapid translational development. EBioMedicine 55:102743 
95. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, et al. (2012) Mesenchymal stem cells 
enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 67:533-539. 
96. Li J, Li D, Liu X, Tang S, Wei F (2012) Human umbilical cord mesenchymal stem cells reduce systemic 
inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 9:33 
97. Liang B, Chen J, Li T, Wu H, Yang W, et al. (2020) Clinical remission of a critically ill COVID-19 patient treated by 
human umbilical cord mesenchymal stem cells. ChinaXiv 2:1. 
98. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, et al. (2020) Transplantation of ACE2(-) Mesenchymal Stem Cells 
Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis 11:216-228 
99. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, et al. (2020) A rapid advice guideline for the diagnosis and treatment 
of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7: 4. 
100. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, et al. (2003) Glycyrrhizin, an active component of 
liquorice roots, and replication of SARS-associated coronavirus. Lancet 361:2045-2046. 
101. Shankar D, Patwardhan B (2017) AYUSH for New India(2020) Vision and strategy. J Ayur int med 8:137. 
102. Sordillo PP, Helson L (2015) Curcumin suppression of cytokine release and cytokine storm. A potential therapy 
for patients with Ebola and other severe viral infections. In Vivo 29:1-4. 
103. Grover A, Agrawal V, Shandilya A, Bisaria VS, Sundar D (2011) Non-nucleosidic inhibition of Herpes simplex 
virus DNA polymerase:mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. 
BMC Bioinformatics 13:S22. 
104. Hemila H, Chalker E (2013) Vitamin C for preventing and treating the common cold. Cochrane Database Syst 
Rev 31:CD000980. 
105. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME (2013) The implication of vitamin D and autoimmunity(2020) 
a comprehensive review. Clin Rev Allergy Immunol 45:217-226 
106. Levy DE, Marie IJ, Durbin JE (2011) Induction and function of type I and III interferon in response to viral 
infection. Curr Opin Virol 1:476-486. 
107. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C (2020) Antiviral activities of type I interferons to 
SARS-CoV-2 infection. Antiviral Res 179:104811. 
108. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, et al. (2004) Inhibition of SARS coronavirus infection in vitro with 
clinically approved antiviral drugs. Emerg Infect Dis 10:581-586. 
109. Keyhan SO, Fallahi HR, Cheshmi B (2020) Dysosmia and dysgeusia due to the 2019 Novel Coronavirus; a 
hypothesis that needs further investigation. Maxillofac Plast Reconstr Surg 42:9 
110. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, et al. (2020) Olfactory and gustatory 
dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19):a 
multicenter European study. Eur Arch Otorhinolaryngol 277:2251-2261 
111. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, et al. (2020) Zinc and respiratory tract 
infections:Perspectives for COVID19 (Review). Int J Mol Med 46:17-26. 
112. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, et al. (2020) Evolution of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic:A global health emergency. Sci 
Total Environ 730:138996. 
113. Yang J, Zheng Y, Gou X, Pu K, Chen Z, et al. (2020) Prevalence of comorbidities and its effects in patients 
infected with SARS-CoV-2(2020) a systematic review and meta-analysis. Int J Infect Dis 94:91-95. 
114. Chen N, Zhou M, Dong X, Qu J, Gong F, et al. (2020) Epidemiological and clinical characteristics of 99 cases of 
2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507-513. 
115. Li M, Dong Y, Wang H, Guo W, Zhou H, et al. (2020) Cardiovascular disease potentially contributes to the 
progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis 30:1061-1067 
116. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, et al. (2020) Clinical characteristics of 140 patients infected with 
SARS-CoV-2 in Wuhan, China. Allergy 75:1730-1741. 
117. Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) Clinical course and risk factors for mortality of adult inpatients 
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062. 
118. Aggarwal G, Cheruiyot I, Aggarwal S, Wong J, Lippi G, et al. (2020) Association of Cardiovascular Disease With 
Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. Curr Probl Cardiol 45: 100617. 
119. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, et al. (2020) Clinical impact of COVID-19 on patients 
with cancer (CCC19): a cohort study. Lancet 395:1907-1918. 
120. Wang T, Du Z, Zhu F, Cao Z, An Y, et al. (2020) Comorbidities and multi-organ injuries in the treatment of 
COVID-19. Lancet 395:e52. 
121. Wang D, Hu B, Hu C, Zhu F, Liu X, et al. (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 
Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061-1069. 
122. Epidemiology Working Group (2020) The epidemiological characteristics of an outbreak of 2019 novel 
coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41:145-151. 
123. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, et al. (2020) Simulation of the clinical and pathological 
manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for 
disease pathogenesis and transmissibility. Clin Infect Dis 26:ciaa325. 
124. Sivaraman D, Pradeep P (2020) Revealing anti-viral potential of Bio-active therapeutics targeting SARS-CoV2-
polymerase (RdRp) in combating COVID-19:Molecular Investigation on Indian traditional medicines. Preprints 
1:2020030450. 
125. Nandan A, Tiwari S, Sharma V (2020) Exploring alternative medicine options for the prevention or treatment of 
coronavirus disease 2019 (COVID-19)-A systematic scoping review. medRxiv 14-1-9. 
126. Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, et al. (2020) The COVID-19 vaccine 
development landscape. Nat Rev Drug Discov 19:305-306. 
127. Garg M, Al-Ani A, Mitchell H, Hendy P, Christensen B (2020) Low population mortality from COVID-19 in 
countries south of latitude 35 degrees North-supports vitamin D as a factor determining severity. Authors' 
reply. Aliment Pharmacol Ther 51:1438-1439. 
128. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, et al. (2020) Evidence that Vitamin D 
Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 12:988. 
129. Munro APS, Faust SN (2020) Children are not COVID-19 super spreaders:time to go back to school. Arch Dis 
Child 105:618-619. 
130. Wong G, Liu W, Liu Y, Zhou B, Bi Y (2015) MERS, SARS, and Ebola:The Role of Super-Spreaders in Infectious 
Disease. Cell Host Microbe 18:398-401. 
131. McCartney DM, Byrne DG (2020) Optimisation of Vitamin D Status for Enhanced Immuno-protection Against 
Covid-19. Ir Med J 113:58. 
132. Wang F, Kream RM, Stefano GB (2020) An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine 
Development. Med Sci Monit 26: e924700. 
133. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, et al. (2020) Immunogenicity of a DNA vaccine candidate for 
COVID-19. Nat Commun 11:2601. 
134. Itani R, Tobaiqy M, Al Faraj A (2020) Optimizing use of theranostic nanoparticles as a life-saving strategy for 
treating COVID-19 patients. Theranostics 10:5932-5942. 
135. Bouchentouf S, Missoum N (2020) Identification of Compounds from Nigella Sativa as New Potential Inhibitors 
of 2019 Novel Coronasvirus (Covid-19):Molecular Docking Study.Chem Revx 13:48. 
136. Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-Ldrissi M, et al. (2020) Moroccan Medicinal plants as 
inhibitors against SARS-CoV-2 main protease:Computational investigations. J Biomol Struct Dyn6:1-9. 
137. https://www.healthysoch.com/ayurveda/indian-traditional-ayurvedic-treatment-regime-for-novel-
coronavirus-covid-19/ 
138. Mpiana PT, Tshibangu DS, Kilembe JT, Gbolo BZ, Mwanangombo DT, et al. (2020) Aloe vera (L.) Burm. F. as a 
Potential Anti-COVID-19 Plant: A Mini-review of Its Antiviral Activity. Euro J Med Plants 86-93. 
139. Pugh N, Ross SA, ElSohly MA, Pasco DS (2001) Characterization of Aloeride, a new high-molecular-weight 
polysaccharide from Aloe vera with potent immunostimulatory activity. J Agri Food Chem 49:1030-1034. 
140. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S (2020) Potential inhibitor of COVID-19 main 
protease (Mpro) from several medicinal plant compounds by molecular docking study. Prepr 20944:1-14. 
141. Tillu G, Chaturvedi S, Chopra A, Patwardhan B (2020) Public health approach of Ayurveda and Yoga for COVID-
19 prophylaxis. J Alter Comp Med 26:360-364. 
142. Balkrishna A, POKHREL S, Singh J, Varshney A (2020) Withanone from Withania somnifera may inhibit novel 
Coronavirus (COVID-19) entry by disrupting interactions between viral S-protein receptor binding domain and 
host ACE2 receptor. 2020. 
143. Goothy SSK, Goothy S, Choudhary A, Potey G, Chakraborty H, et al. (2020) Ayurveda’s Holistic Lifestyle 
Approach for the Management of Coronavirus disease (COVID-19):Possible Role of Tulsi. Int J Res Pharma Sci 
11:16-18. 
144. Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I, et al. (2020) In Search of Preventative Strategies(2020) 
Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway 
Tissues.Prepnts 2020. 
145. Chandel V, Raj S, Rathi B, Kumar D (2020) In Silico Identification of Potent COVID-19 Main Protease Inhibitors 
from FDA Approved Antiviral Compounds and Active Phytochemicals through Molecular Docking:A Drug 
Repurposing Approach. Chem Biol 7:197. 
146. Soar JS (2020) A cost-effective preventative approach to potentially save lives in the coronavirus pandemic, 
jointly using Vitamin D, Curcumin, and Vitamin C,(with updated dosage parameters). IndiaRxiv 6:1. 
147. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, et al. (2020) Is diabetes mellitus associated with mortality 
and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 14:535-545. 
148. Chen P, Zhou B (2020) Clinical characteristics of COVID-19 patients with abnormal liver tests. J Hepatol 73:712-
713. 
149. Yang L, Tu L (2020) Implications of gastrointestinal manifestations of COVID-19. Lancet Gastroenterol Hepatol 
5:629-630. 
150. Mao L, Jin H, Wang M, Hu Y, Chen S, et al. (2020) Neurologic Manifestations of Hospitalized Patients With 
Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 77:683-690. 
151. Henry BM, Lippi G (2020) Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) 
infection. Int Urol Nephrol 52:1193-1194. 
152. Zhang C, Shi L, Wang FS (2020) Liver injury in COVID-19:management and challenges. Lancet Gastroenterol 
Hepatol 5:428-430. 
153. Batu ED, Özen S (2020) Implications of COVID-19 in pediatric rheumatology. Int Rheumatol 2020:1. 
 
 
